One hour alteplase infusion plus low molecular weight heparin versus heparin alone in pulmonary embolism Source: Annual Congress 2003 - Pulmonary hypertension Year: 2003
Comparison between the administration of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) in the treatment of pulmonary embolism Source: Annual Congress 2007 - Venous thromboembolic disease Year: 2007
Low-molecular-weight heparin versus unfractionated heparin in acute pulmonary thromboembolism Source: Eur Respir J 2001; 18: Suppl. 33, 381s Year: 2001
Possible anti-inflammatory activity of low molecular weight heparin in patients with high risk of pulmonary embolism Source: Eur Respir J 2004; 24: Suppl. 48, 684s Year: 2004
Randomized trial of low-molecular-weight heparin compared with unfractionated heparin for acute pulmonary embolism Source: Eur Respir J 2001; 18: Suppl. 33, 382s Year: 2001
Enoxaparin versus unfractionated heparin in acute pulmonary thromboembolism Source: Eur Respir J 2002; 20: Suppl. 38, 237s Year: 2002
Comparison of low-molecular-weight-heparin and unfractionated heparin for acute PTE Source: Eur Respir J 2005; 26: Suppl. 49, 699s Year: 2005
Pulmonary embolism and pregnancy Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=177 Year: 2004
Effectiveness of anticoagulation with unfractionated heparin for acute pulmonary embolism Source: Virtual Congress 2021 – Insights into pulmonary embolism Year: 2021
Anti-inflammatory activity of low molecular weight heparin in patients with exacerbations of COPD Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
Effect of low molecular weight heparins on the development of obliterative airway desease in the rat tracheal transplant model Source: Annual Congress 2009 - Human and experimental lung transplantation: novel findings Year: 2009
Long term treatment of pulmonary embolism (PE) with low molecular weight heparin (LMWH) (tinzaparin). Preliminary results Source: Eur Respir J 2007; 30: Suppl. 51, 80s Year: 2007
Early recognition and treatment of severe sepsis and septic shock in CAP Source: Eur Respir Monogr 2014; 63: 184-204 Year: 2014
Intrapleural heparin or heparin combined with human recombinant DNAase is not effective in the treatment of empyema in a rabbit model Source: Eur Respir J 2006; 28: Suppl. 50, 348s Year: 2006
High molecular weight preparations of hyaluronic acid protect asthmatics from challenge-induced bronchoconstriction, while a low molecucular weight preparation does not Source: Annual Congress 2007 - New drugs for asthma Year: 2007
Direct oral anticoagulants and low-molecular weight heparin for primary prevention of venous thromboembolism in cancer patients: a meta-analysis Source: Virtual Congress 2020 – From diagnosis to management of pulmonary embolism Year: 2020
A prospective study of the use of low molecular weight heparin for prevention of venous thrombo-embolism in breathless patients with limited mobility Source: Annual Congress 2009 - Intensive care unit management and outcome Year: 2009
A clinical comparison of intrapleural heparin versus urokinase in the management of tuberculous pleurisy Source: Eur Respir J 2005; 26: Suppl. 49, 647s Year: 2005
Early discharge of patients with pulmonary embolism: a two-phase observational study Source: Eur Respir J 2007; 30: 708-714 Year: 2007